ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Donald B. Doty
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doty, D. B.
Right arrow Articles by Millar, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doty, D. B.
Right arrow Articles by Millar, R. C.

Ann Thorac Surg 2000;69:739-742
© 2000 The Society of Thoracic Surgeons

Original Articles

Mitral valve replacement with homograft and Maze III procedure

Donald B. Doty, MDa, Karikehalli A. Dilip, MDa, Roger C. Millar, MDa

a Division of Cardiovascular and Thoracic Surgery, Department of Surgery, LDS Hospital, Salt Lake City, Utah, USA

Address reprint requests to Dr Doty, Department of Surgery, LDS Hospital, 324 Tenth Ave #160, Salt Lake City, UT 84103
e-mail: ldddoty{at}ihc.com

Background. Mitral valve disease is often accompanied by atrial fibrillation, which may compromise the patient even after the valvular lesion has been repaired.

Methods. Three patients with rheumatic type mitral valve disease and chronic atrial fibrillation were treated by mitral valve replacement with cryopreserved mitral valve homograft and Maze III procedure, as a method to relieve both the valvular pathology and the rhythm disorder. The patients’ clinical courses have been followed for up to 1 year after operation.

Results. All patients survived operation, and all have normal sinus rhythm. None are taking cardiac medications.

Conclusions. Long-term treatment with warfarin should not be required, and other cardiac medicines may be eliminated following mitral valve replacement with homograft combined with Maze III procedure.




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
S. M. Prasad, H. S. Maniar, C. J. Camillo, R. B. Schuessler, J. P. Boineau, T. M. Sundt III, J. L. Cox, and R. J. Damiano Jr
The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1822 - 1827.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. C. Millar, J. M. Arcidi Jr, and P. J.M. Alison
The maze III procedure for atrial fibrillation: should the indications be expanded?
Ann. Thorac. Surg., November 1, 2000; 70(5): 1580 - 1586.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.